Your in vitro diagnostic (IVD) can use the EU in-house exemption only if the actual manufacturing and use arrangement meets the applicable conditions of Article 5(5) of the In Vitro Diagnostic Medical Devices Regulation (IVDR). It is a route for qualifying health institutions established in the EU, not a label that lets a diagnostic startup supply its device without following the relevant commercial route. IVDR Article 5(5)
If you lead a laboratory or work with one as a diagnostic founder, start with the institution and the movement of the device. You can then separate obligations that apply now from the equivalent-device justification that begins on 31 December 2030. That distinction matters before you commit to a collaboration, an evidence plan or a launch assumption. IVDR Article 113(3)(j).
Do your institution and arrangement qualify?
A health institution is an organisation whose primary purpose is patient care or treatment, or the promotion of public health. The Medical Device Coordination Group (MDCG) explains that this can include laboratories and public health institutes supporting healthcare without treating patients directly. Recognition can depend on national legislation, so neither a company name nor a laboratory address settles the question. IVDR Article 2(29); MDCG 2023-1, section 2, pages 3 to 4.
Write down the answers to these screening questions before relying on the exemption.
- Which legal entity is the qualifying health institution?
- Who manufactures the finished device, and where does the institution use it?
- Does the device leave that legal entity, including within a hospital group?
- What national rules or restrictions apply?
- Could the manufacturing arrangement constitute industrial-scale production?
Article 5(5) requires manufacture and use only within EU-established health institutions, prohibits device transfer to another legal entity and excludes industrial-scale manufacture. Several hospitals can belong to one legal entity, while a single hospital can contain several. MDCG advises checking national interpretation with the competent authority. A shared brand or building is not sufficient evidence. Article 5(5)(a) and final subparagraphs; MDCG sections 3.4 and 3.11.
Do not treat every movement of material as transfer of a device. MDCG distinguishes devices from patient specimens and written protocols, and allows sharing results while locating the reading of results in the manufacturing health institution. Map exactly what crosses the boundary rather than assuming every collaboration is forbidden or permitted. MDCG section 3.1.3, page 5.
Which IVDR in-house exemption conditions apply now?
Most of the operational conditions already apply. The 2030 date concerns one specific condition, Article 5(5)(d), about the target patient group's needs and an equivalent device available on the market. It does not postpone Annex I or give laboratories until 2030 to establish quality systems. Article 113(2), (3)(i) and (j).
| Requirement | Applicability | What to establish |
|---|---|---|
| EU health-institution manufacture/use, no transfer to another legal entity, relevant Annex I requirements, national oversight and no industrial scale | Not deferred by the exceptions for points (b) to (i); general application from 26 May 2022 | Institution, entity boundary, activity and safety/performance evidence |
| Appropriate quality management systems and EN ISO 15189 compliance or applicable national provisions, points (b) and (c) | From 26 May 2024 | Manufacture and use controls, plus laboratory compliance |
| Authority information, public declaration, documentation and manufacture controls, clinical-use review and corrective action, points (e) to (i) | From 26 May 2024 | Records and responsibilities appropriate to each condition, including the class-specific scope of point (g) |
| Documented justification about unmet patient-group needs and equivalent market devices, point (d) | From 31 December 2030 | The specific clinical need and why an equivalent available device cannot meet it at the appropriate performance level |
The table reads Article 5(5) alongside Article 113, not the dates for commercial legacy devices. Regulation (EU) 2024/1860 replaced the earlier 26 May 2028 date for point (d) with 31 December 2030. Amending Regulation, Article 2(5)(e). Older guidance diagrams must not override that amendment.
A deferred point (d) does not remove point (e). Your institution must already provide information on request to its competent authority, including justification of manufacture, modification and use. Preparing a patient-need rationale now is a practical planning choice; describing point (d) itself as already applicable would misstate the timeline. Article 5(5)(d), (e) and Article 113(3)(j).
What evidence needs an owner?
Assign an accountable person to each evidence area before clinical use. The worksheet below is a practical aid, not a mandatory regulatory template or a substitute for national requirements.
| Evidence area | Suggested owner | Question to close |
|---|---|---|
| Institution and legal entity | Institution leadership with legal support | What records establish the institution and every relevant entity boundary? |
| Manufacture and use | Laboratory and manufacturing leads | Who controls the process, changes, release and use? |
| Safety and performance | Scientific lead with quality support | Which Annex I requirements apply, and where is the supporting evidence? |
| Quality management system (QMS) and laboratory compliance | Quality lead | Do controls cover manufacturing as well as laboratory work? |
| Declaration and authority requests | Institution's designated regulatory contact | Who maintains the public declaration and can retrieve the requested records? |
| Clinical-use experience | Clinical and laboratory leads | Who reviews experience and acts on problems? |
| Market alternatives and patient need | Clinical/scientific lead | What patient need and comparison evidence should be maintained ahead of 2030? |
The distinction between manufacturing and laboratory controls is important. Article 5(5)(b) requires appropriate quality management systems for manufacture and use, while point (c) addresses laboratory compliance with EN ISO 15189 or applicable national provisions, including accreditation provisions. MDCG explains that EN ISO 15189 compliance alone does not cover device manufacturing and Annex I compliance. Do not reduce this to “get accredited and you are exempt.” MDCG section 3.5.2, pages 10 to 12.
For class D, point (g) requires documentation explaining the facility, manufacturing process, design, performance and intended purpose in enough detail for authority assessment of Annex I compliance. Member States may extend this requirement to classes A, B or C. Lower classes still need to meet their other applicable conditions and relevant Annex I requirements. Point (h) links manufacturing controls to the documentation referred to in point (g). Article 5(5)(g) and (h).
The public declaration gives the institution's name and address, identifies the devices and declares compliance with relevant Annex I requirements, with reasoned justification where requirements are not fully met. It is not an instruction to publish every technical record. Authorities can request further information, inspect activities and restrict specific device types. Article 5(5)(e), (f) and national-oversight subparagraph.
How would a laboratory and startup test their arrangement?
Consider a fictional EU hospital laboratory developing an assay for a defined patient group. A startup supplies components and proposes a second phase in which finished assay devices go to a separately incorporated partner laboratory. This example is a discussion tool, not a finding that either phase qualifies.
First, the institution's leadership and legal adviser establish the hospital's legal entity and national recognition. The laboratory lead records who turns components into the finished device and where it is used. MDCG recognises manufacture from parts or components, but that does not automatically qualify every supplier relationship. MDCG sections 3.2.1 and 3.4.
Next, the quality and scientific leads map manufacturing controls and relevant Annex I evidence, rather than relying on laboratory accreditation alone. They assign the public declaration and clinical-use review to named institutional owners. These responsibilities remain with the institution under the applicable conditions; a collaboration agreement is not evidence that they have been fulfilled. Article 5(5)(b), (c), (f) and (i).
The proposed second phase raises a different question. If the finished in-house device transfers to another legal entity, it fails point (a)'s no-transfer condition. Sending specimens for analysis or sharing results is a different factual arrangement. Resolve which activity is intended before promising the partner an in-house route. Article 5(5)(a); MDCG section 3.1.3.
Finally, the clinical lead defines the patient need and records potentially equivalent available devices. MDCG recommends a market search and regular review. Treat this as guidance-informed preparation, without bringing forward point (d)'s statutory 2030 date. If eligibility remains unresolved, take the actual process and entity map to a qualified adviser and, where appropriate, the national competent authority. MDCG section 3.6; Article 113(3)(j).
Where does this fit in your regulatory plan?
An in-house eligibility assessment answers who can manufacture and use a particular device under specified conditions. It does not decide a commercial product's entire regulatory strategy. If your plan includes supplying devices outside the institution, separate that route before budgeting for it.
For a broader market decision, read EU or FDA first for your medical device?. For an introduction to quality-system choices, read eQMS for medical device startups. That software guide does not establish EN ISO 15189 compliance or in-house eligibility. If you are weighing external regulatory help for a commercial device, Envoy versus a regulatory consultant addresses that resourcing decision.
Sources and further reading
- Regulation (EU) 2017/746, consolidated 10 January 2025, Articles 2, 5 and 113, EU legislation for definitions, conditions and applicability. Consolidations are documentation tools; authentic Official Journal acts govern.
- Regulation (EU) 2024/1860, Article 2(5)(e), the authentic amendment establishing the current point (d) date.
- MDCG 2023-1, non-binding guidance explaining institutional boundaries, QMS and evidence. Its 2023 timetable predates the date amendment.
- European Commission July 2024 transitional Q&A, Part E, question 18, an explanation of the 2030 applicability date.